Celldex Therapeutics, Inc. (NASDAQ:CLDX) Short Interest Update

Celldex Therapeutics, Inc. (NASDAQ:CLDX) was the recipient of a significant growth in short interest in December. As of December 31st, there was short interest totaling 8,244,450 shares, a growth of 20.1% from the December 15th total of 6,865,432 shares. Based on an average trading volume of 672,703 shares, the days-to-cover ratio is presently 12.3 days. Approximately 13.0% of the shares of the stock are short sold. Approximately 13.0% of the shares of the stock are short sold. Based on an average trading volume of 672,703 shares, the days-to-cover ratio is presently 12.3 days.

Celldex Therapeutics Price Performance

CLDX stock opened at $25.14 on Wednesday. The company has a 50 day moving average price of $26.56 and a 200 day moving average price of $24.98. Celldex Therapeutics has a fifty-two week low of $14.40 and a fifty-two week high of $30.50. The stock has a market capitalization of $1.67 billion, a PE ratio of -7.44 and a beta of 1.19.

Celldex Therapeutics (NASDAQ:CLDX) last released its earnings results on Monday, November 10th. The biopharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.13). Celldex Therapeutics had a negative net margin of 3,446.88% and a negative return on equity of 33.22%. As a group, equities analysts expect that Celldex Therapeutics will post -2.48 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Richard M. Wright sold 49,298 shares of Celldex Therapeutics stock in a transaction dated Thursday, November 13th. The shares were sold at an average price of $24.00, for a total transaction of $1,183,152.00. Following the completion of the transaction, the insider directly owned 20,833 shares of the company’s stock, valued at $499,992. This trade represents a 70.29% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 4.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Hennion & Walsh Asset Management Inc. increased its holdings in Celldex Therapeutics by 31.2% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 46,965 shares of the biopharmaceutical company’s stock valued at $1,276,000 after purchasing an additional 11,182 shares during the last quarter. Mirador Capital Partners LP raised its position in shares of Celldex Therapeutics by 2.9% in the 4th quarter. Mirador Capital Partners LP now owns 170,659 shares of the biopharmaceutical company’s stock valued at $4,635,000 after acquiring an additional 4,738 shares during the period. Overbrook Management Corp boosted its stake in Celldex Therapeutics by 31.1% during the 4th quarter. Overbrook Management Corp now owns 11,537 shares of the biopharmaceutical company’s stock worth $313,000 after acquiring an additional 2,740 shares during the last quarter. SG Americas Securities LLC grew its holdings in Celldex Therapeutics by 143.2% during the fourth quarter. SG Americas Securities LLC now owns 47,340 shares of the biopharmaceutical company’s stock valued at $1,286,000 after purchasing an additional 27,872 shares during the period. Finally, Tudor Investment Corp ET AL bought a new stake in Celldex Therapeutics in the third quarter valued at approximately $818,000.

Wall Street Analyst Weigh In

Several research analysts have recently commented on CLDX shares. Barclays boosted their target price on Celldex Therapeutics from $21.00 to $24.00 and gave the stock an “underweight” rating in a report on Wednesday, December 17th. Mizuho assumed coverage on Celldex Therapeutics in a research report on Tuesday, October 21st. They issued an “outperform” rating and a $48.00 price objective for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Celldex Therapeutics in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Celldex Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $44.10.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.